anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Three-dimensional contrast-enhanced fusion ultrasound (CEFUS) of atherosclerotic carotid arteries provides spatial visualization of the vessel lumen, creating a lumenography. As in 3-D computed tomography angiography (CTA), 3-D CEFUS outlines the contrast-filled lumen. Plaque and vessel contours are distinguished in 3-D CEFUS, allowing plaque volume quantification as a valid estimate of carotid plaque burden. Three-dimensional CEFUS is unproven in intermodality studies, vindicating the assessment of 3-D CEFUS applicability and comparing 3-D CEFUS and 3-D CTA lumenography as a proof-of-concept study.
METHODS: Using an ultrasound system with magnetic tracking, a linear array transducer and SonoVue contrast agent, 3-D CEFUS acquisitions were generated by spatial stitching of serial 2-D images. From 3-D CEFUS and 3-D CTA imaging, the atherosclerotic carotid arteries were reconstructed with lumenography in an offline software program for lumen and plaque volume quantification. Bland-Altman analysis was used for inter-image modality agreement.
RESULTS: The study included 39 carotid arteries. Mean lumen and plaque volume in 3-D CEFUS were 0.63 cm3 (standard deviation [SD]: 0.26) and 0.62 cm3 (SD: 0.26), respectively. Lumen volume differences between 3-D CEFUS and 3-D CTA were non-significant, with a mean difference of 0.01 cm3 (SD: 0.02, p = 0.26) and limits of agreement (LoA) range of ±0.11 cm3. Mean plaque volume difference was -0.12 cm3 (SD: 0.19, p = 0.006) with a LoA range of ±0.39 cm3.
CONCLUSION: There was strong agreement in lumenography between 3-D CEFUS and 3-D CTA. The interimage modality difference in plaque volumes was substantial because of challenging vessel wall definition in 3-D CTA. Three-dimensional CEFUS is viable in quantifying carotid plaque volume burden and can potentially monitor plaque development over time.
PURPOSE:To obtain the title factor in high yield and purity, by passing a material containing epithelial growth factor and existing in the submandibular gland, urine and milk of animals through an adsorption column bonded with a specific immune antibody. CONSTITUTION:The spleen cell of an expterimental animal (e.g. mouse) immunized with epithelial growth factor (EGF) is fused with a myeloma cell, and a monoclonal antibody obtained from the obtained hybridoma (hybrid cell) is bonded to an absortion (e.g. Affi-Gel, sephadex, etc.). A material containing EGF is contacted with said absorbent to effect the adsorption of EGF. The absorbed EGF is eluted to obtain EGF as on eluted fraction. When the obtained EGF contains impurity proteins, it is purified by gel-filtration treatment, etc. EFFECT:Since the EGF is adsorbed specifically to a monoclonal anti-EGF antibody, it can be adsorbed in high efficiency by passing through an adsorption column only once.
With the rapid development of information technology, great changes have taken place in the way of managing, analyzing, and using data in all walks of life. Using deep learning algorithm for data analysis in the field of medicine can improve the accuracy of disease recognition. The purpose is to realize the intelligent medical service mode of sharing medical resources among many people under the dilemma of limited medical resources. Firstly, the Digital Twins module in the Deep Learning algorithm is used to establish the medical care and disease auxiliary diagnosis model. With the help of the digital visualization model of Internet of Things technology, data is collected at the client and server. Based on the improved Random Forest algorithm, the demand analysis and target function design of the medical and health care system are carried out. Based on data analysis, the medical and health care system is designed using the improved algorithm. The results show that the intelligent medical service platform can collect and analyze the clinical trial data of patients. The accuracy of improved ReliefF & Wrapper Random Forest (RW-RF) for sepsis disease recognition can reach about 98%, and the accuracy of algorithm for disease recognition is also more than 80%, which can provide better technical support for disease recognition and medical care services. It provides a solution and experimental reference for the practical problem of scarce medical resources.
Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.
Mild fever may occur after large I.M. doses. Hyperpyrexia has been reported. Increases in appetite and weight sometimes occur. Peripheral edema and a systemic lupus erythematosus-like syndrome have been reported.

Note: There have been occasional reports of sudden death in patients receiving phenothiazines. In some cases, the cause appeared to be cardiac arrest or asphyxia due to failure of the cough reflex.
A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
PROBLEM TO BE SOLVED: To obtain a new compound selectively acting on liver and useful for treatment or the like of fibrosis disease of the liver as a strong prolyl-4- hydroxylase inhibitor hardly causing adiposis. SOLUTION: This new compound is the compound of formula I (R<1> is H or chlorine; R<2> is H, a 1-8C alkyl or the like; R<3> is H, cyano or the like; R<4> and R<5> are each H, bromine or the like) or a salt thereof, e.g. N-((1-chloro-4- hydroxyisoquinolin-3-yl)carbonyl)glycine. The compound of formula I is obtained by reacting quinoline-2-carboxylic acid of formula II with an amino ester of the formula; H2 N-CH2 -CO2 R (R is H, benzyl or the like) to provide an amidoester of formula III, and separating the compound of formula I from the ester of formula III. The separation of the compound of formula I from the ester of formula III is ordinary carried out by hydrolysis of the ester of formula III. The daily dose is 1-5 mg/kg in a case of an oral administration, and 0.5-1 mg/kg in a case of parenteral administration.
The invention discloses a traditional Chinese medicine composition for treating cardiovascular diseases. The traditional Chinese medicine composition comprises 20-80 percent by weight of isorhamnetin and 20-80 percent by weight of quercetin. The invention also discloses a preparation method of the traditional Chinese medicine composition. The preparation method comprises the following steps: extracting total flavones of hippophae, separating the isorhamnetin and the quercetin, and preparing the finished product according to a formula. The traditional Chinese medicine composition disclosed by the invention has high purity and low dose. Compared with a conventional hippophae total flavone extractive preparation, the traditional Chinese medicine composition has a better curative effect and is more controllable in quality and suitable for industrial production.
The invention discloses acupuncture liquid medicine for curing toothache and a preparation method of acupuncture liquid medicine. The acupuncture liquid medicine is prepared from the following raw materials in parts by weight: 39-41 parts of herba verbenae, 39-41 parts of zanthoxyli pericarpium, 39-41 parts of flos caryophylli, 39-41 parts of herba serissa serissoides, 39-41 parts of flos lonicerae japonicae, 39-41 parts of radix stemonae, 39-41 parts of radix et rhizoma rhei, 39-41 parts of folium isatidis, 39-41 parts of negundo chastetree fruit, 39-41 parts of rhizoma anemarrhenae, 44-46 parts of radix et rhizoma salvia miltiorrhizae, 44-46 parts of radix scutellariae, 44-46 parts of herba patriniae, 44-46 parts of herba asari, 44-46 parts of radix paeoniae rubra, 44-46 parts of rhizoma rehmannia, 44-46 parts of olibanum, 44-46 parts of myrrha, 44-46 parts of herba scutellariae barbatae, 44-46 parts of radix notoginseng, 49-51 parts of radix aconiti, 49-51 parts of radix angelicae pubescentis, 49-51 parts of radix saposhnikoviae, 49-51 parts of radix aconiti praeparata, 49-51 parts of Chinese angelica, 49-51 parts of rhizoma chuanxiong, 49-51 parts of rhizoma curcumae longae and 49-51 parts of cortex moutan. The medical materials which are prepared according to medicine ingredients and parts by weight are cut into slices and then evenly mixed with 250 parts of vinegar, stood and moistened. After the vinegar is absorbed completely, the medical materials are arranged in a heating container to be fried in a temperature of 150-170 DEG C. When the surfaces of the medical materials become yellow or deep color, the medical materials are taken out and aired. The dry medical materials are smashed to 110-115 mesh particles, 1250 parts of baijiu with alcoholic content of 55-60% are added to soak the medical materials for 3-5 days, and the liquid medicine is obtained after the medical materials are filtered out. The liquid medicine is free of toxic and side effect, quick in curing effect, obvious in curing effect and suitable for toothache patients.
Standard therapy where the use of SGLT2i at randomization is not encouraged but RAASi and beta-blockers (except for maximal dosage) are allowed. Prescription or up-titration of the study drugs listed under Intensive Treatment is not encouraged. If investigators/treating physicians feel that further prescription or up-titration is required, a thorough justification is mandatory. Unless there is clinically irrefutable reason, every attempt should be made to use other blood pressure lowering drugs than RAASi or beta-blockers, as well as glucose lowering drugs than SGLT2i, in the control group.
One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.
NEW MATERIAL:A monoclonal antibody, prepared by immunizing an animal in a state of autoimmune disease or genetically susceptible to the autoimmune disease with a hormone or enzyme in an immunologically tolerant state and capable of exhibiting specificity for the hormone or enzyme in the immunologically tolerant state. USE:A reagent for purifying hormones or enzymes, e.g. insulin or aequorin, in an immunologically tolerant state. PREPARATION:For example, an animal, e.g. mouse, in a state of autoimmune disease or genetically susceptible to the autoimmune disease is immunized with a hormone or enzyme, e.g. insulin or aequorin, in an immunologically tolerant state for normal animals of the same species as the above-mentioned animal and cells, capable of producing antibodies and obtained by cloning a hybridoma formed from cells, capable of producing the antibodies and collected from the above-mentioned immunized animal and myelomatous cells are cultivated to afford the aimed monoclonal antibodies.
The CSAC group (chlorhexidine-based soap + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
Dual therapy of lisinopril and telmisartan treatments. Standard blood pressure control of 110-130/80 mm Hg.
The invention belongs to the field of daily necessities, and particularly relates to a plant type no-clean antibacterial disinfectant and a preparation method thereof. The raw materials used in the invention are all green plant components, all belong to food-grade substances, and are non-toxic, alcohol-free, chloric acid-free, corrosion-free, odor-free, non-irritant, non-explosive and non-side-effect. The pH value of the no-clean antibacterial disinfectant is 3-6, and the no-clean antibacterial disinfectant is safe and mild and has no hidden trouble. The sterilization rate of the sterilization agent to salmonella (common pathogenic bacteria), colibacillus, mycete (fungus) and other bacteria is as high as 99.9%. The components of the invention are used as main materials and combined with different auxiliary materials to prepare bacteriostatic disinfectants in different forms such as spray type, gel type, liquid type, foam type and the like. The product of the invention is widely used for disinfecting hands, tableware, vehicles and large indoor spaces of all people including children over 3 years old, pregnant women and the like, kindergartens, schools, military camps, hotels and the like, and can also be used for disinfecting and inhibiting bacteria in water quality of a humidifier.
AIM: To study the clinical characteristics and prognosis of patients with functional class (FC) III-IV chronic heart failure (CHF) who meet the criteria for inclusion in the palliative care program.
MATERIAL AND METHODS: A short registry of severe CHF forms was conducted at 60 outpatient and inpatient clinics in the Samara region for one month (16.05.2022-15.06.2022). The registry included patients with FC III-IV CHF who sought medical help during that period. Lethal outcomes were assessed at 90 days after the inclusion in the registry using the Mortality Information and Analytics system.
RESULTS: 591 patients (median age, 71.0 [64.0; 80.0] years were enrolled, including 339 (57.4%) men, of which 149 (24.1%) were of working age (under 65 years). The main cause of CHF was ischemic heart disease (64.5%). 229 (38.7%) patients had left ventricular ejection fraction <40%. During the past year, 513 (86.8%) patients had at least one hospitalization for decompensated CHF. 45.7% of patients had hydrothorax, and 11.3% of patients had ascites. Low systolic blood pressure was observed in more than 25% of patients; 14.2% required in-hospital inotropic support; and 9.1% received it on the outpatient basis. 4.2% of patients received outpatient oxygen support and 0.8% required the administration of narcotic analgesics. 12 (1.9%) patients were on the waiting list for heart transplantation. In this study, there was an inconsistency in the number of patients with ventricular tachycardia and/or left bundle branch block (LBBB) who were implanted with cardiac resynchronization therapy devices (CRTD) or an implantable cardioverter defibrillator (ICD), a total of 19 patients (11 patients with CRTD and 8 patients with ICD), while 58 (9.8%) patients had indications for CRTD/ICD implantation. Within 90 days from inclusion in the registry, 59 (10.0%) patients died. According to binary logistic regression analysis, the presence of LBBB, hydrothorax, the requirement for outpatient oxygen support, and a history of cardiac surgery were associated with a high risk of death.
CONCLUSION: Patients with severe forms of CHF require not only adequate drug therapy, but also dynamic clinical observation supplemented with palliative care aimed at improving the quality of life, including the ethical principles of shared decision-making and advance care planning to identify the priorities and goals of patients in relation to their care.
Anti-PD-1 and anti-PD-L1 antibodies targeting the immuno-inhibitory PD-1 pathway (thus activating T cells) have achieved clinical success in many types of cancers. However, studies have shown that anti-TIGIT antibodies not only trigger T cells and Natural Killer(NK) cells, but they can also activate T cells to a greater extent than anti-PD-1 antibodies. Therefore, further clinical investigation of anti-TIGIT antibodies such as BAT6021 is warranted.

PD-1 and TIGIT are commonly co-expressed in T cells of the same tumor; thus, combining anti-TIGIT antibodies with PD-1/PD-L1 inhibitors may be a more effective cancer treatment. Indeed, anti-TIGIT antibodies have demonstrated synergy with anti-PD-1/PD-L1 antibodies in preclinical models. In addition, sponsor have shown that single administration of BAT1308 or BAT6021 could not effectively inhibit CT26 tumor growth in PD-1/TIGIT- humanized syngeneic mice; however, the combination treatment resulted in potent anti-tumor activity. Therefore, combined treatment with BAT6021 and an anti-PD-1/PD-L1 antibody like BAT1308 could improve therapeutic outcomes.
Primary Dysmenorrhea: For the treatment of primary dysmenorrhea, beginning with the earliest onset of such pain, ibuprofen oral suspension should be given in a dose of 400 mg every 4 hours, as necessary, for the relief of pain.

Rheumatoid Arthritis and Osteoarthritis: Suggested dosage: 1200 to 3200 mg daily (300 mg q.i.d. or 400 mg, 600 mg or 800 mg t.i.d. or q.i.d.). Individual patients may show a better response to 3200 mg daily, as compared with 2400 mg, although in well-controlled clinical trials patients on 3200 mg did not show a better mean response in terms of efficacy. Therefore, when treating patients with 3200 mg/day, the physician should observe sufficient increased clinical benefits to offset potential increased risk.

Individualization of Dosage: The dose of ibuprofen oral suspension should be tailored to each patient, and may be lowered or raised from the suggested doses depending on the severity of symptoms either at time of initiating drug therapy or as the patient responds or fails to respond.

One fever study showed that, after the initial dose of ibuprofen oral suspension, subsequent doses may be lowered and still provide adequate fever control.

In a situation when low fever would require the ibuprofen oral suspension 5 mg/kg dose in a child with pain, the dose that will effectively treat the predominant symptom should be chosen.

In chronic conditions, a therapeutic response to ibuprofen therapy is sometimes seen in a few days to a week, but most often is observed by two weeks. After a satisfactory response has been achieved, the patient's dose should be reviewed and adjusted as required.

Patients with rheumatoid arthritis seem to require higher doses than do patients with osteoarthritis. The smallest dose of ibuprofen oral suspension that yields acceptable control should be employed.

Ibuprofen oral suspension may be used in combination with gold salts and/or corticosteroids.
The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof for the preparation of a medicament for one or more of: treatment and/or prevention of loss of body weight and body fat, prophylaxis or treatment of cachexia, stimulation of appetite, stimulation of food intake, stimulation of weight gain, or increasingly body fat mass, or increasing body lean mass. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to the use of a ghrelin splice variant-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to a number of new ghrelin splice variant-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin splice variant-like compounds. ® KIPO & WIPO 2009
The present study is divided into 2 parts. Part A is a randomized, double blind, placebo controlled, sequential ascending single and multiple oral doses design to evaluate the safety, tolerability, PK, and food effect of MB-110 in healthy volunteers.Part A will recruit 2 groups (Groups 1 and 2) of 8 healthy volunteers in each group. Within each group, 8 subjects will be randomized 6:2 to receive MB-110 versus placebo.Subjects in Group 1 will receive either 50 mg of MB-110 or placebo under fasted conditions during the first visit (Cohort 1); and either 50 mg of MB-110 or placebo under fed conditions during the second visit (Cohort 3) where food effect will be evaluated. Subjects in Group 2 will receive either 100 mg of MB-110 or placebo under fasted condition during the first visit (Cohort 2); or 200 mg of MB-110 or placebo under fasted condition during the second visit (Cohort 4). In Cohort 5, 8 subjects will be selected from Group 1, Group 2, or new recruitment if the washout time is insufficient from the previous cohort. Subjects in Cohort 5 will be randomized 6:2 to receive MB-110 at dose of 200 mg or placebo once daily for 5 consecutive days.

Part B is a randomized, double-blind, placebo-controlled, multiple ascending oral dose design to evaluate the safety, tolerability, PK, and antiviral activity of MB-110 in subjects infected with Hepatitis C virus genotype 1b, 2a, and 3a.Part B will recruit 3 cohorts (Cohorts 6, 7, and 8) of treatment-naïve HCV infected subjects in each cohort. In Cohort 6, 12 subjects infected with Hepatitis C virus genotype 1b will be randomized 5:5:2 to receive two dose levels of MB-110 or placebo once daily for 3 consecutive days. In Cohort 7, 6 subjects infected with Hepatitis C virus genotype 2a will be randomized 5:1 to receive MB-110 or placebo once daily for 3 consecutive days. In Cohort 8, 6 subjects infected with Hepatitis C virus genotype 3a will be randomized 5:1 to receive MB-110 or placebo once daily for 3 consecutive days.